The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 28, 2017

Filed:

Feb. 21, 2008
Applicants:

Alena Donda, Auboranges, CH;

Jean-pierre Mach, Bellevue, CH;

Kathrin Stirnemann, Zurich, CH;

Inventors:

Alena Donda, Auboranges, CH;

Jean-Pierre Mach, Bellevue, CH;

Kathrin Stirnemann, Zurich, CH;

Assignee:

VACCINEX, INC., Rochester, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/385 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01); C07K 16/32 (2006.01);
U.S. Cl.
CPC ...
A61K 39/385 (2013.01); A61K 39/39 (2013.01); C07K 16/32 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/55594 (2013.01); A61K 2039/6018 (2013.01); C07K 2319/00 (2013.01);
Abstract

The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a β2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy.


Find Patent Forward Citations

Loading…